New combo therapy aims to beat back tough lymphomas

NCT ID NCT07077512

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two drugs—a CAR-T cell therapy (relmacabtagene autoleucel) and a PD-1 inhibitor (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma. The goal is to see if the combo can shrink tumors and improve survival. Participants receive the CAR-T infusion first, then start the PD-1 inhibitor about a month later, continuing for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cell therapy (relmacabtagene autoleucel) plus a PD-1 inhibitor (sintilimab)
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat B-cell lymphomas that have not responded to standard therapies.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from CAR-T therapy and PD-1 inhibitors can be serious, including immune reactions and organ inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA (FL) LARGE B CELL DIFFUSE LYMPHOMA MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Locations

Fifth Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITING

Guangzhou, 510060, China
Guangzhou overseas Chinese hospital
NOT_YET_RECRUITING

Guangzhou, 510632, China
Sun Yat-sen Universitiy Cancer Center
RECRUITING

Guangzhou, 51000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.